MLchartDataset catalogue

Patent · US11020458B2 · B2 · US

Factor VIII polymer conjugates

(11) Publication number
US11020458B2
(21) Application number
16/285,394
(22) Filing date
2019-02-26
(30) Priority date
2006-03-31
(43) Publication date
2021-06-01
(45) Date of grant
2021-06-01
(51) IPC
A61K 38/37; A61K 47/60; A61K 47/61; C07K 14/745
(52) CPC
  • A61K Preparations for medical, dental or toiletry purposes: 38/37, 38/00, 38/18, 47/50, 47/60, 47/61
  • A61P Specific therapeutic activity of chemical compounds or medicinal preparations: 7/00, 7/04
  • C07K Peptides: 14/745, 14/755
(73) Assignee
Takeda Pharmaceutical Co Ltd
(72) Inventors
Peter Turecek; Juergen Siekmann
(54) Title
Factor VIII polymer conjugates
(57) Abstract

The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.

Full text
View on Google Patents

Claims (1)

  1. A composition comprising: (a) a Factor VIII molecule; and (b) at least one water soluble polymer bound to said Factor VIII molecule, wherein said water soluble polymer is attached to the Factor VIII via an oxidized carbohydrate moiety; wherein said water soluble polymer is selected from the group consisting of polyethylene glycol (PEG), polysialic acid (PSA) and dextran; wherein said water soluble polymer is linear; wherein said water soluble polymer has a molecular weight of 2,000 to 150,000 Da; wherein the Factor VIII is a recombinant Factor VIII; wherein said molecule retains at least 50% of native FVIII activity; and said composition is substantially free from albumin.

Description

This application is a continuation of U.S. application Ser. No. 15/213,802, filed on Jul. 19, 2016, (now abandoned), which is a continuation of U.S. application Ser. No. 14/736,870, filed on Jun. 11, 2015, (now abandoned), which is a continuation of U.S. application Ser. No. 13/756,856, filed Feb. 1, 2013, (now abandoned), which is a continuation of U.S. application Ser. No. 13/243,550, filed Sep. 23, 2011, (now abandoned), which is a continuation of U.S. application Ser. No. 13/010,627, filed Jan. 20, 2011 (now issued as U.S. Pat. No. 8,071,728), which is a divisional of U.S. application Ser. No. 12/684,536, filed Jan. 8, 2010 (now issued as U.S. Pat. No. 8,003,760), which is a divisional of U.S. application Ser. No. 12/184,567, filed Aug. 1, 2008 (now issued as U.S. Pat. No. 7,645,860), which is a continuation-in-part of U.S. application Ser. No. 11/729,625, filed on Mar. 29, 2007, (now issued as U.S. Pat. No. 7,683,158) which claims priority to U.S. Provisional Application Nos. 60/790,239 and 60/787,968, which were filed on Apr. 6, 2006 and Mar. 31, 2006, respectively, and U.S. application Ser. No. 13/010,627, filed Jan. 20, 2011, is a divisional of U.S. application Ser. No. 12/184,567, filed Aug. 1, 2008, (now issued as U.S. Pat. No. 7,645,860).

The present invention relates to a proteinaceous construct comprising coagulation factor VIII (FVIII) being bound to at least one water soluble polymer, including a poly(alkylene oxide) such as polyethylene glycol.

Citations (93)

  • US4179337A
  • US4356170A
  • US4757006A
  • US4965199A
  • US5618788A
  • US4970300A
  • WO1986006096A1
  • US5198349A
  • US5250421A
  • US5470954A
  • US5470954C1
  • EP0306968A2
  • US5605884A
  • US4877608A
  • US5153265A
  • US5122614A
  • WO1991009122A1
  • US5328694A
  • US5198493A
  • US5492821A
  • WO1992016555A1
  • US5539063A
  • US5565427A
  • US5565427C1
  • US5846951A
  • WO1993000357A1
  • US6037452A
  • WO1994005332A2
  • US5733873A
  • US5919766A
  • EP0605963A2
  • US5298643A
  • WO1994015626A1
  • WO1994015625A1
  • US5621039A
  • WO1994029370A1
  • US5969040A
  • US6566506B2
  • WO1996010584A1
  • WO1996040731A1
  • US6379933B1
  • US6048720A
  • WO1997011957A1
  • EP1260582A1
  • EP1258497A2
  • US6005077A
  • EP0774261A2
  • WO1997019701A2
  • US6864350B2
  • WO1998025969A1
  • WO1998038218A1
  • US6872393B2
  • US6743908B2
  • US6183738B1
  • EP0977584A1
  • US20060286634A1
  • US6455639B1
  • WO2000023114A2
  • US6692931B1
  • WO2000049047A1
  • WO2000048635A1
  • US6586573B1
  • WO2001005434A2
  • US7338788B2
  • US7230081B1
  • WO2001037893A1
  • US6806063B2
  • US6586398B1
  • US7118737B2
  • US20040247634A1
  • US6913915B2
  • US20040132640A1
  • US20050106658A1
  • WO2003040211A2
  • US20030143596A1
  • US20040235734A1
  • WO2004075923A2
  • US7199223B2
  • WO2004081053A1
  • WO2004089280A2
  • WO2005032581A2
  • WO2005058366A2
  • WO2006071801A2
  • US20060160948A1
  • US7645860B2
  • WO2007126808A1
  • US20090076237A1
  • US20070244301A1
  • WO2008025856A2
  • WO2008074032A1
  • US9492555B2
  • US8642737B2
  • US20170349644A1
Record as JSON
{
  "publication_number": "US11020458B2",
  "country": "US",
  "kind": "B2",
  "title": "Factor VIII polymer conjugates",
  "abstract": "The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.",
  "claims": [
    "1. A composition comprising: (a) a Factor VIII molecule; and (b) at least one water soluble polymer bound to said Factor VIII molecule, wherein said water soluble polymer is attached to the Factor VIII via an oxidized carbohydrate moiety; wherein said water soluble polymer is selected from the group consisting of polyethylene glycol (PEG), polysialic acid (PSA) and dextran; wherein said water soluble polymer is linear; wherein said water soluble polymer has a molecular weight of 2,000 to 150,000 Da; wherein the Factor VIII is a recombinant Factor VIII; wherein said molecule retains at least 50% of native FVIII activity; and said composition is substantially free from albumin."
  ],
  "description_excerpt": "This application is a continuation of U.S. application Ser. No. 15/213,802, filed on Jul. 19, 2016, (now abandoned), which is a continuation of U.S. application Ser. No. 14/736,870, filed on Jun. 11, 2015, (now abandoned), which is a continuation of U.S. application Ser. No. 13/756,856, filed Feb. 1, 2013, (now abandoned), which is a continuation of U.S. application Ser. No. 13/243,550, filed Sep. 23, 2011, (now abandoned), which is a continuation of U.S. application Ser. No. 13/010,627, filed Jan. 20, 2011 (now issued as U.S. Pat. No. 8,071,728), which is a divisional of U.S. application Ser. No. 12/684,536, filed Jan. 8, 2010 (now issued as U.S. Pat. No. 8,003,760), which is a divisional of U.S. application Ser. No. 12/184,567, filed Aug. 1, 2008 (now issued as U.S. Pat. No. 7,645,860), which is a continuation-in-part of U.S. application Ser. No. 11/729,625, filed on Mar. 29, 2007, (now issued as U.S. Pat. No. 7,683,158) which claims priority to U.S. Provisional Application Nos. 60/790,239 and 60/787,968, which were filed on Apr. 6, 2006 and Mar. 31, 2006, respectively, and U.S. application Ser. No. 13/010,627, filed Jan. 20, 2011, is a divisional of U.S. application Ser. No. 12/184,567, filed Aug. 1, 2008, (now issued as U.S. Pat. No. 7,645,860).\n\nThe present invention relates to a proteinaceous construct comprising coagulation factor VIII (FVIII) being bound to at least one water soluble polymer, including a poly(alkylene oxide) such as polyethylene glycol.",
  "cpc": [
    "A61K 38/37",
    "A61K 38/00",
    "A61K 38/18",
    "A61K 47/50",
    "A61K 47/60",
    "A61K 47/61",
    "A61P 7/00",
    "A61P 7/04",
    "C07K 14/745",
    "C07K 14/755"
  ],
  "ipc": [
    "A61K 38/37",
    "A61K 47/60",
    "A61K 47/61",
    "C07K 14/745"
  ],
  "assignees": [
    "Takeda Pharmaceutical Co Ltd"
  ],
  "inventors": [
    "Peter Turecek",
    "Juergen Siekmann"
  ],
  "filing_date": "2019-02-26",
  "publication_date": "2021-06-01",
  "grant_date": "2021-06-01",
  "priority_date": "2006-03-31",
  "application_number": "US-201916285394-A",
  "family_id": "41404469",
  "cited_by_count": 9,
  "citations": [
    "US4179337A",
    "US4356170A",
    "US4757006A",
    "US4965199A",
    "US5618788A",
    "US4970300A",
    "WO1986006096A1",
    "US5198349A",
    "US5250421A",
    "US5470954A",
    "US5470954C1",
    "EP0306968A2",
    "US5605884A",
    "US4877608A",
    "US5153265A",
    "US5122614A",
    "WO1991009122A1",
    "US5328694A",
    "US5198493A",
    "US5492821A",
    "WO1992016555A1",
    "US5539063A",
    "US5565427A",
    "US5565427C1",
    "US5846951A",
    "WO1993000357A1",
    "US6037452A",
    "WO1994005332A2",
    "US5733873A",
    "US5919766A",
    "EP0605963A2",
    "US5298643A",
    "WO1994015626A1",
    "WO1994015625A1",
    "US5621039A",
    "WO1994029370A1",
    "US5969040A",
    "US6566506B2",
    "WO1996010584A1",
    "WO1996040731A1",
    "US6379933B1",
    "US6048720A",
    "WO1997011957A1",
    "EP1260582A1",
    "EP1258497A2",
    "US6005077A",
    "EP0774261A2",
    "WO1997019701A2",
    "US6864350B2",
    "WO1998025969A1",
    "WO1998038218A1",
    "US6872393B2",
    "US6743908B2",
    "US6183738B1",
    "EP0977584A1",
    "US20060286634A1",
    "US6455639B1",
    "WO2000023114A2",
    "US6692931B1",
    "WO2000049047A1",
    "WO2000048635A1",
    "US6586573B1",
    "WO2001005434A2",
    "US7338788B2",
    "US7230081B1",
    "WO2001037893A1",
    "US6806063B2",
    "US6586398B1",
    "US7118737B2",
    "US20040247634A1",
    "US6913915B2",
    "US20040132640A1",
    "US20050106658A1",
    "WO2003040211A2",
    "US20030143596A1",
    "US20040235734A1",
    "WO2004075923A2",
    "US7199223B2",
    "WO2004081053A1",
    "WO2004089280A2",
    "WO2005032581A2",
    "WO2005058366A2",
    "WO2006071801A2",
    "US20060160948A1",
    "US7645860B2",
    "WO2007126808A1",
    "US20090076237A1",
    "US20070244301A1",
    "WO2008025856A2",
    "WO2008074032A1",
    "US9492555B2",
    "US8642737B2",
    "US20170349644A1"
  ]
}

Record 1,617 of 8,000 in Patents full text (MLC-0201). Request the full dataset.